Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease

Background: The efficacy of upadacitinib in patients with Crohn’s disease (CD) has been shown in pivotal randomized controlled trials. However, real-world data is needed to assess its effectiveness and safety in routine clinical care with biologic-experienced patients. This study aimed to evaluate t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Janina Lüke, Clara Zippel, Phil-Robin Tepasse, Frank Lenze, Markus Strauss, Arne Bokemeyer, Joost Buskermolen, Tina Schomacher, Julia Fischer, Jonel Trebicka, Richard Vollenberg
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-02-01
coleção:	Diseases
Assuntos:	Crohn’s disease Janus kinase (JAK) inhibitors upadacitinib
Acesso em linha:	https://www.mdpi.com/2079-9721/14/2/54
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!